SCHEMBL2403758

SCHEMBL2403758

O=C1Cc2ccc(Cl)cc2CCN1Cc1c[nH]cn1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.34
HTR2A P28223 2/20 0.33
HTR2C P28335 2/20 0.33
HTR2B P41595 2/20 0.33
DDB1 Q16531 2/20 0.33
CRBN Q96SW2 2/20 0.33
SRD5A1 P18405 7/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
SRD5A2 P31213 2/20 0.32
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31
OPRK1 P41145 1/20 0.31
OPRL1 P41146 1/20 0.31
ACACB O00763 1/20 0.31
CMA1 P23946 1/20 0.31
AHR P35869 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21708179 0.93 ACHE (0.34) TRPV1HTR2AHTR2CHTR2BSRD5A1
SCHEMBL16057972 0.84 DDB1 (0.39) DDB1CRBNDRD2DRD4
SCHEMBL2405422 0.82 SRD5A1 (0.36) TRPV1HTR2AHTR2CHTR2BSRD5A1
SCHEMBL30361111 0.82 SRD5A1 (0.36) TRPV1HTR2AHTR2CHTR2BSRD5A1
SCHEMBL3529313 0.82 TRPV1 (0.49) TRPV1HTR2AHTR2CHTR2BSRD5A1
SCHEMBL3530913 0.82 HTR2A (0.48) TRPV1HTR2AHTR2CHTR2BDRD2
Hydrochloric Acid SCHEMBL3047348 0.81 SRD5A1 (0.35) TRPV1HTR2AHTR2CHTR2BSRD5A1
SCHEMBL13229480 0.75 TRPV1 (0.41) TRPV1HTR2AHTR2CHTR2B
SCHEMBL13229479 0.73 CDK9 (0.38) TRPV1HTR2AHTR2CHTR2B
SCHEMBL3049624 0.73 TRPV1 (0.36) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2021-08-12 US disclosed
EP-3827820-A1 BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2021-06-02 EP disclosed
US-10806717-B2 Methods and compositions for improving cognitive function THE JOHNS HOPKINS UNIVERSITY (US) 2020-10-20 US disclosed
US-10624875-B2 Methods and compositions for treating schizophrenia THE JOHNS HOPKINS UNIVERSITY (US) 2020-04-21 US disclosed
EP-3610890-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA The Johns Hopkins University (US) 2020-02-19 EP disclosed
US-10154988-B2 Methods and compositions for treating schizophrenia THE JOHNS HOPKINS UNIVERSITY (US) 2018-12-18 US disclosed
US-20150313876-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA THE JOHNS HOPKINS UNIVERSITY 2015-11-05 US disclosed
US-20140206667-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA THE JOHNS HOPKINS UNIVERSITY 2014-07-24 US disclosed
EP-2672822-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2013-12-18 EP disclosed
US-20120214859-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2012-08-23 US disclosed
WO-2012109491-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-16 WO disclosed
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY (US) 2011-09-01 US disclosed
US-20100222326-A1 New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders UCB PHARMA, S.A. (BE) 2010-09-02 US disclosed
EP-2152262-A2 NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS UCB Pharma, S.A. (BE) 2010-02-17 EP disclosed
WO-2008132139-A2 NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS UCB PHARMA S.A. (BE) 2008-11-06 WO disclosed
WO-2008132142-A2 NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS UCB PHARMA S.A. (BE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10806717-B2 Methods and compositions for improving cognitive function GRIN2A, CHRNA2, SYNGR2 TRPV1 3864/4885HTR2A 48/4885HTR2C 171/4885
US-20150313876-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA RAB2A, SYNGR2, GRIN2A TRPV1 2131/4885HTR2A 5/4885HTR2C 47/4885
US-10154988-B2 Methods and compositions for treating schizophrenia RAB2A, SYNGR2, GRIN2A TRPV1 2131/4885HTR2A 5/4885HTR2C 47/4885
US-20210244709-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 TRPV1 3864/4885HTR2A 48/4885HTR2C 171/4885
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A TRPV1 3918/4885HTR2A 12/4885HTR2C 93/4885
US-10624875-B2 Methods and compositions for treating schizophrenia RAB2A, SYNGR2, GRIN2A TRPV1 2052/4885HTR2A 5/4885HTR2C 27/4885
US-20140206667-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA RAB2A, SYNGR2, GRIN2A TRPV1 2052/4885HTR2A 5/4885HTR2C 27/4885
US-20100222326-A1 New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders CNR2, CNR1, SLC18A2 TRPV1 174/4885HTR2A 33/4885HTR2C 21/4885
US-20120214859-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, GRIN2D, SLC18A2 TRPV1 1893/4885HTR2A 54/4885HTR2C 250/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 TRPV1 3864/4885HTR2A 48/4885HTR2C 171/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE TRPV1 2309/4885HTR2A 16/4885HTR2C 124/4885
US-20110212928-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE TRPV1 2309/4885HTR2A 16/4885HTR2C 124/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 TRPV1 1517/4885HTR2A 69/4885HTR2C 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.